Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea

• Published in: The European respiratory journal Vol. 55; no. 1; p. 1901320
• Main Authors: Eastwood, Peter R., Barnes, Maree, MacKay, Stuart G., Wheatley, John R., Hillman, David R., Nguyên, Xuân-Lan, Lewis, Richard, Campbell, Matthew C., Pételle, Boris, Walsh, Jennifer H., Jones, Andrew C., Palme, Carsten E., Bizon, Alain, Meslier, Nicole, Bertolus, Chloé, Maddison, Kathleen J., Laccourreye, Laurent, Raux, Guillaume, Denoncin, Katleen, Attali, Valérie, Gagnadoux, Frédéric, Launois, Sandrine H.
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society 01.01.2020
• Subjects: Animal biology; Cellular Biology; Food and Nutrition; Life Sciences; Original; Pharmaceutical sciences
• ISSN: 0903-1936; 1399-3003; 1399-3003
• DOI: 10.1183/13993003.01320-2019

Hypoglossal nerve stimulation (HNS) decreases obstructive sleep apnoea (OSA) severity genioglossus muscle activation and decreased upper airway collapsibility. This study assessed the safety and effectiveness at 6 months post-implantation of a novel device delivering bilateral HNS a small implanted electrode activated by a unit worn externally, to treat OSA: the Genio™ system. This prospective, open-label, non-randomised, single-arm treatment study was conducted at eight centres in three countries (Australia, France and the UK). Primary outcomes were incidence of device-related serious adverse events and change in the apnoea-hypopnoea index (AHI). The secondary outcome was the change in the 4% oxygen desaturation index (ODI). Additional outcomes included measures of sleepiness, quality of life, snoring and device use. This trial was registered with ClinicalTrials.gov, number NCT03048604. 22 out of 27 implanted participants (63% male, aged 55.9±12.0 years, body mass index (BMI) 27.4±3.0 kg·m ) completed the protocol. At 6 months BMI was unchanged (p=0.85); AHI decreased from 23.7±12.2 to 12.9±10.1 events·h , a mean change of 10.8 events·h (p<0.001); and ODI decreased from 19.1±11.2 to 9.8±6.9 events·h , a mean change of 9.3 events·h (p<0.001). Daytime sleepiness (Epworth Sleepiness Scale; p=0.01) and sleep-related quality of life (Functional Outcomes of Sleep Questionnaire-10; p=0.02) both improved significantly. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35%. 91% of participants reported device use >5 days per week, and 77% reported use for >5 h per night. No device-related serious adverse events occurred during the 6-month post-implantation period. Bilateral HNS using the Genio™ system reduces OSA severity and improves quality of life without device-related complications. The results are comparable with previously published HNS systems despite minimal implanted components and a simple stimulation algorithm.